Zoetis Inc Stock Today
| ZTS Stock | USD 176.96 0.25 0.14% |
Performance0 of 100
| Odds Of DistressLess than 6
|
Zoetis is selling for under 176.96 as of the 23rd of November 2024; that is 0.14 percent increase since the beginning of the trading day. The stock's lowest day price was 176.28. Zoetis has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Note, on August 21, 2024, Representative Jared Moskowitz of US Congress acquired under $15k worth of Zoetis Inc's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of February 2013 | Category Healthcare | Classification Health Care |
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. The company has 451.16 M outstanding shares of which 4.32 M shares are at this time shorted by investors with about 2.45 days to cover. More on Zoetis Inc
Moving together with Zoetis Stock
Moving against Zoetis Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Zoetis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Kristin Peck | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Zetes Industries SA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, SP 500 Index, Obamacare Repeal, SRI Sustainable Growth, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsZoetis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Zoetis' financial leverage. It provides some insight into what part of Zoetis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zoetis Inc (ZTS) is traded on New York Stock Exchange in USA. It is located in 10 Sylvan Way, Parsippany, NJ, United States, 07054 and employs 14,100 people. Zoetis is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 79.84 B. Zoetis Inc runs under Pharmaceuticals sector within Health Care industry. The entity has 451.16 M outstanding shares of which 4.32 M shares are at this time shorted by investors with about 2.45 days to cover.
Zoetis Inc has about 3.58 B in cash with 2.35 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.88.
Check Zoetis Probability Of Bankruptcy
Ownership AllocationZoetis Inc retains a total of 451.16 Million outstanding shares. The majority of Zoetis outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zoetis Inc to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zoetis Inc. Please pay attention to any change in the institutional holdings of Zoetis Inc as this could imply that something significant has changed or is about to change at the company. Please note that on August 21, 2024, Representative Jared Moskowitz of US Congress acquired under $15k worth of Zoetis Inc's common stock.
Check Zoetis Ownership Details
Zoetis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Polen Capital | 2024-09-30 | 6.4 M | |
| Northern Trust Corp | 2024-09-30 | 5.7 M | |
| Norges Bank | 2024-06-30 | 5 M | |
| Mizuho Securities Usa Inc | 2024-09-30 | 4.9 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 4.8 M | |
| Nuveen Asset Management, Llc | 2024-06-30 | 4.8 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 4.7 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 4.7 M | |
| Unisphere Establishment | 2024-06-30 | 4.5 M | |
| Vanguard Group Inc | 2024-09-30 | 41.2 M | |
| Blackrock Inc | 2024-06-30 | 36.8 M |
Zoetis Historical Income Statement
Zoetis Stock Against Markets
Zoetis Corporate Directors
| William Steere | Independent Director | Profile | |
| Linda Rhodes | Independent Director | Profile | |
| Frank DAmelio | Independent Director | Profile | |
| Robert Scully | Independent Director | Profile |
Already Invested in Zoetis Inc?
The danger of trading Zoetis Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zoetis is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zoetis. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zoetis Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Zoetis Stock Analysis
When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.